Exchange Announcement • 21 Sep 2026 18:11
Caliway Is Invited To Attend The Online Investor Conference Held By Yuanta Securities On September 29, 2026
Exchange Announcement • 21 Sep 2026 17:54
The Final Statistical Results Of Cbl-514 Phase Ii Clinical Trial For Dercum'S Disease Demonstrate Statistical Significance On Primary Efficacy Endpoint.
Exchange Announcement • 18 Sep 2026 17:19
Approval Of Canada Hc Protocol Amendment For The Clinical Study Cbl-0302, A Cbl-514 Pivotal Phase 3 Clinical Study For Reducing Abdominal Subcutaneous Fat.
Exchange Announcement • 14 Sep 2026 17:44
Fda Ind Protocol Amendment For Cbl-514 Pivotal Phase 3 Study (Cbl-0302) In Abdominal Subcutaneous Fat Reduction Clears 30-Day Review Period
Exchange Announcement • 28 Aug 2026 17:22